Market report: £10bn wiped off AstraZeneca as drug trial flops
Drugs giant AstraZeneca (AZN) sees its share price collapse in early trade on Thursday as word breaks of a failed clinical trial. The stock crashes nearly 16%, or 810.5p, to £43.025 as the group confirms that combining two...
27 July 2017